Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor. Academic Article uri icon

Overview

abstract

  • c-KIT activating mutations cause resistance to PARP inhibitor in AML1-ETO–positive leukemias. c-KIT inhibitor avapritinib downregulates BRCA1/2 and DNA-PK catalytic subunit to restore the sensitivity to PARP inhibitor.

publication date

  • December 10, 2019

Research

keywords

  • Core Binding Factor Alpha 2 Subunit
  • Leukemia
  • Oncogene Proteins, Fusion
  • Poly(ADP-ribose) Polymerase Inhibitors
  • RUNX1 Translocation Partner 1 Protein

Identity

PubMed Central ID

  • PMC6963253

Scopus Document Identifier

  • 85076356933

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2019000756

PubMed ID

  • 31816060

Additional Document Info

volume

  • 3

issue

  • 23